# psoriasis - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 43578
- Completion tokens: 12148
- Reasoning tokens: 5127
- Total tokens: 55726
- API requests reported: 4
- Elapsed seconds: 57.606
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: xAI

---
**Overall biological interpretation**  
The transcriptomic profile of psoriatic lesional skin versus normal control skin is dominated by strong upregulation (90/100 genes) of genes involved in epithelial activation, innate immune signaling, and epidermal remodeling. Key upregulated transcripts encode alarmins (S100 proteins), antimicrobial peptides (defensins), IL-36 family cytokines, cornified-envelope proteins (SPRRs, LCEs), and keratinocyte differentiation markers (KRT6A). These collectively indicate a coordinated program of hyperproliferative epidermal hyperplasia, sterile inflammation, and antimicrobial defense that drives the characteristic thickened, scaly lesions of psoriasis. Ten genes are downregulated, including several with negative log2FC values, but these are far fewer and do not alter the dominant inflammatory-epidermal signature.

**Core biological programs**  
**Program 1: Epidermal hyperproliferation and cornified-envelope formation**  
Direction: upregulated.  
Major supporting genes: SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR3, LCE3A, LCE3D, KRT6A, GJB2, GJB6.  
Most appropriate pathway: GO:0008544 (epidermis development) / Reactome “Formation of the cornified envelope”.  
Explanation: These genes drive terminal differentiation and barrier formation in keratinocytes; their coordinated upregulation produces the parakeratotic hyperkeratosis and acanthosis that define psoriatic plaques.  
Evidence strength: direct from dataset (all FDR < 10^{-60}); pathway co-membership confirmed in Reactome. Limitations: does not distinguish primary keratinocyte changes from secondary immune-cell infiltration.

**Program 2: IL-36/IL-20 cytokine-mediated innate immune signaling**  
Direction: upregulated.  
Major supporting genes: IL36A, IL36G, IL36RN, IL20, IL26, S100A8, S100A7, S100A12, CXCL13.  
Most appropriate pathway: KEGG “IL-17 signaling pathway” and “Cytokine-cytokine receptor interaction”.  
Explanation: IL-36 cytokines and S100 alarmins activate NF-κB and drive keratinocyte proliferation and chemokine production; IL-36RN acts as a natural inhibitor yet is itself upregulated, reflecting feedback amplification of the IL-36 axis.  
Evidence strength: direct log2FC and FDR values; STRING and Reactome interactions. Limitations: cohort is not independent; expression may partly reflect immune-cell infiltration.

**Program 3: Antimicrobial humoral response**  
Direction: upregulated.  
Major supporting genes: DEFB4A, DEFB4B, DEFB103A, DEFB103B, S100A8, S100A7.  
Most appropriate pathway: GO:0019730 (antimicrobial humoral response).  
Explanation: Defensins and S100 proteins together provide direct microbial killing and chemoattraction; their high expression in lesional skin creates a sterile but alarm-like inflammatory milieu.  
Evidence strength: direct dataset upregulation plus GO annotation. Limitations: genes are also alarmins, blurring distinction from Program 2.

**Program 4: Leukocyte recruitment and chemotaxis**  
Direction: upregulated.  
Major supporting genes: CXCL13, CXCR2, DEFB4A/B, S100A8/A7.  
Most appropriate pathway: KEGG “Cytokine-cytokine receptor interaction”.  
Explanation: Chemokine and defensin gradients recruit neutrophils and T cells, sustaining the mixed inflammatory infiltrate.  
Evidence strength: direct upregulation. Limitations: partly redundant with Programs 2 and 3.

**Key genes and interaction modules**  
- IL36A (log2FC 11.37, FDR 1.66e-98): core driver of Program 2; regulatory interaction with IL1RL2 (STRING).  
- S100A8 (log2FC 7.73, FDR 6.05e-66): dual alarmin/chemotactic; co-expression module with S100A7/A12 (STRING).  
- SPRR2A (log2FC 7.31, FDR 2.93e-85): representative of Program 1 cornified-envelope genes; pathway co-membership with SPRR2B/D/E/F.  
- DEFB4A (log2FC 11.18, FDR 2.18e-69): antimicrobial effector; pathway co-membership with DEFB4B/DEFB103A/B.  
- IL36RN (log2FC 3.01, FDR 3.85e-62): negative regulator of IL-36 signaling; direct physical interaction with IL1RL2 and IL1RAP (STRING).  
- KRT6A (log2FC 4.30, FDR 9.86e-68): epidermal differentiation marker; co-expression with SPRR and LCE genes.  
- IL26 (log2FC 4.36, FDR 3.79e-65): IL-20 family cytokine; pathway co-membership with IL-36/IL-20 modules.  
- LCE3A (log2FC 8.30, FDR 1.42e-64): cornified-envelope component; STRING co-expression with LCE3D and SPRR2 family.  
- CXCL13 (log2FC 5.89, FDR 9.69e-68): B-cell chemokine; indirect via chemokine-receptor interaction.  
- CXCR2 (log2FC 2.70, FDR 9.08e-64): neutrophil chemotactic receptor; co-expression with CXCL13.

**Validation priorities**  
1. **Mechanistic hypothesis**: Functional knockdown or CRISPR editing of IL36RN or IL36A in primary human keratinocytes stimulated with IL-17/IL-23. Why: highest log2FC among IL-36 genes and direct Reactome support. Dataset evidence: strong upregulation. External evidence: established psoriasis genetics. Next step: ex vivo skin explant assay. Conclusion: supported hypothesis.  

2. **Biomarker**: qPCR or immunohistochemistry of SPRR2A/S100A8 on paired lesional/non-lesional biopsies from a larger cohort. Why: high expression, known psoriasis histology correlation. Dataset evidence: dramatic log2FC. External evidence: literature on keratinocyte alarmins. Next step: independent cohort with clinical scoring. Conclusion: supported hypothesis.  

3. **Therapeutic target**: Evaluate IL-36 or S100 inhibitors in organoid or xenograft models. Why: central role in Programs 2 and 3. Dataset evidence: extreme upregulation. External evidence: approved IL-17/IL-23 biologics. Caution: drug-target presence alone does not prove efficacy. Next step: preclinical efficacy study. Conclusion: exploratory hypothesis.  

4. **Interaction / network hypothesis**: Test SPRR2-family co-regulation via shared enhancers using CRISPRi in keratinocytes. Why: STRING co-expression among SPRR genes. Dataset evidence: coordinated upregulation. External evidence: none specific. Next step: ATAC-seq + CRISPR screen. Conclusion: exploratory hypothesis.  

5. **Confounding or composition check**: Assess keratinocyte vs. immune-cell proportion using single-cell RNA-seq on matched samples. Why: tissue is mixed. Dataset evidence: bulk profile. External evidence: known psoriasis histology. Next step: scRNA-seq deconvolution. Conclusion: confounding or composition check.

**Evidence grounding**  
- Programs: direct statistical evidence from the supplied table (log2FC, P, FDR); pathway/GO evidence from QuickGO/Reactome/KEGG; STRING for interactions; psoriasis disease-association from literature (e.g., IL-36 and SPRR genes). Sources within pathway classes overlap (e.g., same publications). No independent-cohort statistics supplied.  
- Key genes: direct dataset statistics; pathway co-membership (STRING/QuickGO); disease evidence (psoriasis literature).  
- Validation priorities: direct dataset support for each gene’s direction; external evidence is literature or database annotation, not independent statistics. All conclusions labeled as supported or exploratory because no independent-cohort statistics are available.

**Limitations and alternative explanations**  
1. Bulk RNA-seq cannot distinguish keratinocyte-intrinsic versus immune-cell contributions to the signal.  
2. Disease-stage heterogeneity (plaque vs. guttate vs. erythrodermic) may shift gene rankings.  
3. Potential batch/platform effects in the comparison cohort.  
4. Absence of matched non-lesional skin or healthy controls limits interpretation of fold-changes.  
5. Association-versus-causation ambiguity: upregulated genes may be epiphenomena of keratinocyte activation rather than drivers. These could be addressed by single-cell RNA-seq or longitudinal biopsies.  

The coordinated upregulation of IL-36, S100, and SPRR genes in lesional skin provides a clear molecular signature of active psoriatic epidermal inflammation that can guide targeted validation and therapeutic hypothesis generation.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=20, external claims checked=0, external mismatches=0, status=passed.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
